Engineered ApoEV-laden hydrogel microspheres mitigate nucleus pulposus cell ferroptosis and inflammation in intervertebral disc degeneration.
Background
Intervertebral disc degeneration (IVDD) is a prevalent age-related disorder, often characterized by chronic inflammation and the premature aging (senescence) of nucleus pulposus cells (NPCs). A key pathological mechanism driving NPC senescence and IVDD progression is ferroptosis, a form of iron-dependent regulated cell death. Current treatments often fall short in directly addressing these cellular mechanisms. This study explores a novel strategy to reduce ferroptosis and delay NPC senescence by leveraging the therapeutic potential of apoptotic extracellular vesicles (ApoEVs) and anti-inflammatory agents.
Study Design
Researchers developed injectable hydrogel microspheres (HMs) designed to target senescent NPCs. These HMs integrated two key therapeutic components: senescent NPC-targeting ApoEVs, which served as a delivery vehicle for the ferroptosis-regulating enzyme Glutathione Peroxidase 4 (GPX4), and diclofenac sodium (DFS), an anti-inflammatory drug. The ApoEVs were further modified with a reactive oxygen species (ROS)-responsive and senescent NPC-targeting peptide to enhance their efficacy. The study utilized in vivo experiments to evaluate the system's impact on IVDD progression and employed single cell RNA sequencing (scRNA-seq) to analyze cellular changes and pathway modulation.
Results
The engineered senescence-targeting system demonstrated significant therapeutic effects in mitigating IVDD progression. The modified ApoEVs effectively reduced NPC ferroptosis and reversed senescence-related metabolic dysfunction and cellular damage. In vivo experiments, supported by scRNA-seq analysis, revealed that the system significantly attenuated both ferroptosis and inflammatory pathways. The upregulation of GPX4 delivered by ApoEVs was identified as a key mechanism in counteracting ferroptosis. This comprehensive approach led to a marked reduction in the burden of senescent NPCs and a deceleration of the degenerative process within the intervertebral discs, highlighting the multi-faceted benefits of targeting both ferroptosis and inflammation. The treatment prevented the transformation of inflammatory NPC phenotypes, thereby offering opportunities for reducing senescent NPCs from ferroptosis and mitigating IVDD progression.
Key Findings
- Engineered ApoEVs delivered GPX4 and diclofenac sodium via injectable hydrogel microspheres.
- The system significantly attenuated ferroptosis in nucleus pulposus cells (
NPCs). - Treatment reduced
inflammatory pathwaysand prevented inflammatoryNPCphenotype transformation. - The intervention mitigated the progression of intervertebral disc degeneration (IVDD)
in vivo.
Why It Matters
This research introduces a highly targeted and multi-modal strategy for intervertebral disc degeneration (IVDD), moving beyond symptomatic relief to address core pathological mechanisms like ferroptosis and senescence. The use of ApoEVs as a natural delivery system, combined with a targeting peptide and an anti-inflammatory drug, represents a sophisticated approach to localized therapy. For future clinical translation, this work suggests a potential for injectable, minimally invasive treatments that could halt or even reverse IVDD progression, offering a significant improvement over current surgical or palliative options. While still in preclinical stages, the concept of engineered vesicles delivering specific proteins and drugs to senescent cells holds promise for regenerative medicine and targeted therapies for age-related degenerative diseases.